---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-028337"
form_type: "8-K"
ticker: "QTRX"
cik: "0001503274"
company_name: "Quanterix Corp"
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:57:04.141318+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Quanterix Q4 rev +35% non-GAAP, CEO Hrusovsky becomes Exec Chair, Toloue CEO, Lilly deal $11M

## Summary
- Q4 GAAP total revenue $30.3M (+16% YoY); non-GAAP total revenue $29.3M (+35% YoY).
- FY 2021 GAAP total revenue $110.6M (+28% YoY); product revenue $81.1M (+84% YoY).
- CEO Kevin Hrusovsky becomes Executive Chairman; President Masoud Toloue succeeds as CEO and joins Board, effective April 25, 2022.
- Collaboration with Eli Lilly: non-exclusive license to P-tau217 antibody technology; Lilly funds $11M development this year.

## SEC filing metadata
- accession: 0001104659-22-028337
- form_type: 8-K
- ticker: QTRX
- cik: 0001503274
- company_name: Quanterix Corp
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503274/000110465922028337/0001104659-22-028337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503274/000110465922028337/tm226991d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-028337
- JSON: https://secwatch.observer/filing/0001104659-22-028337.json
- Plain text: https://secwatch.observer/filing/0001104659-22-028337.txt

## Key facts
- Executive change
  Kevin Hrusovsky changed role as Executive Chairman at Quanterix Corp.
  - Action: become
  - Role: Executive Chairman
  source text: Effective April 25, 2022, Chairman and Chief Executive Officer Kevin Hrusovsky will become Executive Chairman of the Board of Directors, and President of Quanterix and Diagnostics Masoud Toloue will succeed Mr. Hrusovsky as Chief Executive Officer and join Quanterix’ Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503274/000110465922028337/0001104659-22-028337-index.htm
- Executive change
  Masoud Toloue was appointed as Chief Executive Officer at Quanterix Corp.
  - Action: succeed
  - Role: Chief Executive Officer
  source text: and President of Quanterix and Diagnostics Masoud Toloue will succeed Mr. Hrusovsky as Chief Executive Officer and join Quanterix’ Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503274/000110465922028337/0001104659-22-028337-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.